Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Targeted Agent Combination in a Molecularly Defined Acute Leukemia
Distinguishing what a product is authorized to do elsewhere from what an IND investigates is a recurring discipline in annual reporting. This article prepares the regulatory operations components of an annual report for a hypothetical open IND in which an oral targeted agent is studied in combination with standard therapy in adults with a molecularly defined acute leukemia, a use not covered by any marketing authorization. The single Phase 2 study has entered 48 of 120 planned participants. The article reconciles study accounting, reports validated hypothetical safety tables with attention to treatment-specific monitoring events, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and explains the difference between the annual general investigational plan and the plan in the initial IND, and builds a timeline to an October 31, 2026 deadline.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Peivand Pirouzi
- Daxaben Jigneshkumar Patel
- Junyi Wu
- Atchaya Ravichandran
- Nilukshan Sugumar
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24421699
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00